Galectin Therapeutics Inc.GALTNASDAQ

Revenue (LTM)

Net Income (LTM)

$-47M

-14.6% YoY

Free Cash Flow

$-42M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.0B)

Unprofitable

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Revenue	0	0	0	0	0
Gross Profit	-0	-0↓13.9%	-0↑22.0%	-0↓3.1%	-0↓12.1%
Operating Income	-23	-30↓28.7%	-38↓27.1%	-38↑0.7%	-42↓11.5%
Net Income	-23	-31↓30.1%	-39↓27.0%	-41↓5.9%	-47↓14.6%
EBITDA	-23	-30↓28.5%	-38↓25.7%	-38↓1.4%	-41↓8.4%
EPS Diluted	-0.41	-0.52↓26.8%	-0.65↓25.0%	-0.74↓13.8%	-0.76↓2.7%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Cash & Equivalents	27	40↑46.1%	19↓53.1%	26↑38.0%	15↓41.1%
Total Current Assets	29	42↑41.9%	21↓50.9%	28↑34.8%	17↓37.7%
Total Assets	30	42↑41.3%	21↓49.1%	28↑32.5%	17↓38.0%
Total Current Liabilities	5	9↑67.3%	13↑44.0%	16↑20.5%	35↑125.9%
Total Liabilities	5	39↑625.2%	53↑36.4%	88↑65.4%	121↑36.3%
Total Equity	24	3↓89.2%	-32↓1330.7%	-60↓87.1%	-103↓71.1%
Total Debt	0	29↑65936.4%	40↑37.2%	72↑80.1%	106↑48.0%
Net Debt	-27	-11↑60.9%	21↑300.9%	46↑116.9%	91↑97.5%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-21	-24↓18.0%	-31↓27.8%	-33↓6.1%	-42↓26.7%
Capital Expenditure	0	0	0	0	0
Free Cash Flow	-21	-24↓18.0%	-31↓27.8%	-33↓6.1%	-42↓26.7%
Stock-Based Comp	2	2↑15.4%	3↑38.1%	2↓21.1%	2↑8.2%
Net Change in Cash	-20	13↑161.5%	-21↓268.4%	7↑133.6%	-11↓249.1%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance